Response Biomedical Corp. (TSX: RBM, OTCQB: RPBIF) develops, manufactures and markets the RAMP® system, a rapid diagnostics platform that delivers lab quality performance for efficient patient management in acute care settings.
RAMP® is a global leader in cardiovascular point of care (POC) testing with a wide range of markers available on the platform including Troponin I, CK-MB, Myoglobin, NT-proBNP and D-dimer. For effective and efficient patient care, RAMP® tests aid in the rapid diagnosis of Acute Myocardial Infarction and Heart Failure. RAMP® is ideally suited for both laboratory use and POC testing; POC has the potential to reduce turn around times, increase operational efficiency and improve patient outcomes.
Manufactured in a world class facility in Vancouver, Canada, RAMP® tests are of the highest quality and can be run on either the portable, battery-operated, single-port RAMP® reader or the high throughput, modular, RAMP® 200 reader which has additional compliance features and enhanced connectivity. In addition to cardiovascular tests, RAMP® is sold worldwide for use in infectious disease testing, biodefense and environmental applications. The RAMP® system requires no calibration or maintenance, is easy to use, cost-effective and has minimal service requirements.
When speed, precision and accuracy is critical, the RAMP® platform provides clinicians the results they need for making informed patient management decisions.